Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Background:
Chemotherapy (CT) alone was previously standard first-line (1L) therapy for metastatic nonsmall-cell lung cancer (NSCLC) but alternative treatments, including immunotherapy (I-O), are now available.
Patients & methods:
In this retrospective study, adults with stage IV NSCLC who initiated 1L treatment between 1 August 2018 and 31 December 2019 and had ≥ 2 visits were identified in the Flatiron database. Patients were followed up until 30 June 2020. Baseline characteristics and treatment patterns were described by treatment group: CT, I-O + CT, I-O monotherapy and other.
Results:
Approximately 20% of patients received 1L CT in the 2018–2019 timeframe studied; these patients tended to have squamous histology and low ( ≤ 49%) programmed death ligand-1 expression.
Conclusion: A proportion of p…